Novo Nordisk stock trades down as price remains far below long-term average

Traders Union
All News
Financial News
Novo Nordisk slides 1.15% today

Highlights

Novo Nordisk repurchased 1,239,849 B shares for DKK 369.7 million, advancing its DKK 15 billion buyback program amid weak price action.
A net transfer of 204,498 shares to employee incentives occurred independently, with treasury stock holdings rising to 33.18 million shares by May 13, 2026.
Despite some short-term bullish technicals, sellers remain dominant and the stock is likely to consolidate between $43.90 and $45.40 with downside risk prevailing.

Buybacks accumulate as selling pressure dampens price response

Novo Nordisk completed the repurchase of 1,239,849 B shares for DKK 369,728,627 from May 6 to May 13, 2026, executing its ongoing DKK 15 billion 12-month share buyback programme. During the same period, a net transfer of 204,498 shares occurred under employee incentive arrangements, conducted independently from the main repurchase initiative. As of May 13, 2026, the company reported holding 33,184,329 B shares as treasury stock, with cumulative repurchases reaching 15,999,028 shares valued at DKK 4.17 billion since February 2026, though price action has remained under broader selling pressure.

Bullish MACD meets oversold signals amid post-open weakness

On the technical front, NVO sits above the SMA-20 ($43.46) and SMA-50 ($40.09), while remaining below the SMA-200 ($49.12). The D1 Ichimoku Kijun at $42.37 offers immediate support. Daily MACD shows strong bullish momentum, although the ADX at 21.54 (Buy) reflects only a mild trend. RSI on D1 stands at 56.04, suggesting conditions are neutral-to-bullish. In contrast, D1 Stoch RSI and BBP both indicate oversold, seller-dominated conditions and potential for downside exhaustion. The Awesome Oscillator is neutral and CCI does not offer a strong directional cue. The session opened just below the previous close with moderate volatility, as the price lingers near today's low ($43.97–$45.09), reflecting ongoing post-open pressure. Short-term momentum remains mixed: MACD signals bullishness, while BBP and Stoch RSI signal sellers are still dominant amid daily losses.

Downside bias dominates as breakout odds remain limited

Looking ahead to the coming week, NVO is expected to stay within a typical volatility band of $43.90 to $45.40, based on recent trading ranges and current levels. The likelihood of a price increase is considered low (less than 20%), with technical signals on both daily and weekly timeframes favoring further declines. In a consolidation scenario, the stock will likely fluctuate sideways within the $43.90–$45.40 range. A bullish breakout would require a sustained move above the Ichimoku Kijun and short-term resistance, opening the possibility for advances beyond $45.40. Alternatively, a close beneath immediate support at $43.90 may accelerate declines in line with the prevailing longer-term downtrend.

Anton Kharitonov, expert at Traders Union, sees that Novo Nordisk is absorbing supply through steady buybacks, yet this has not protected the share price from persistent downside. He notes that technical momentum is mixed, with buyers lacking conviction as daily losses continue and most indicators lean bearish or neutral. The price remains capped under the SMA-200, suggesting that bulls need a clear breakout above resistance to change the trend. "Base case remains for a defensive posture — unless NVO can reclaim strength above $45.40, I expect more sideways-to-lower trade."

Previously it was reported that Novo Nordisk was included among select branded medications featured in the Trump administration’s expanded direct-to-consumer prescription program, reflecting the company's ongoing prominence in accessible healthcare initiatives. With Novo Nordisk now completing a significant tranche of its share buyback program amid persistent selling pressure, traders should closely monitor whether a break below $43.90 triggers the next leg down, in line with the prevailing long-term downtrend.

Source of Data: NVO Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.